# Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

> **NCT05222932** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **TILT Biotherapeutics Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Melanoma
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** TILT-123
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT05222932
- **Lead sponsor:** TILT Biotherapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-08
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222932, "Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05222932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*